Morgan Stanley Downgrades ACADIA Pharmaceuticals to Equal-Weight, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has downgraded ACADIA Pharmaceuticals from Overweight to Equal-Weight and lowered the price target from $28 to $20.
August 07, 2024 | 9:29 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley analyst Jeffrey Hung has downgraded ACADIA Pharmaceuticals from Overweight to Equal-Weight and reduced the price target from $28 to $20.
The downgrade from Overweight to Equal-Weight and the significant reduction in the price target from $28 to $20 by a major financial institution like Morgan Stanley is likely to negatively impact investor sentiment and the stock price of ACADIA Pharmaceuticals in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100